Do analysts prefer ONCO or PPCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Propanc Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ONCO or PPCB?

In the previous week, Propanc Biopharma had 1 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Onconetix. Onconetix's average media sentiment score of 0.93 beat Propanc Biopharma's score of 0.44 indicating that Onconetix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Propanc Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ONCO or GOVX?

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 22,976.92%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has stronger valuation & earnings, ONCO or GOVX?

Onconetix has higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Onconetix $810K 3.09 -$14.03M $248.12 0.00 GeoVax Labs N/A N/A -$21.47M -$11.34 N/A

Is ONCO or GOVX more profitable?

GeoVax Labs has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Onconetix -1,575.89% -91.95% -53.76% GeoVax Labs N/A -743.64% -394.74%

Does the media prefer ONCO or GOVX?

In the previous week, GeoVax Labs had 4 more articles in the media than Onconetix. MarketBeat recorded 6 mentions for GeoVax Labs and 2 mentions for Onconetix. Onconetix's average media sentiment score of 0.93 beat GeoVax Labs' score of 0.35 indicating that Onconetix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Onconetix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GeoVax Labs 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend ONCO or DCOY?

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 883.93%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Decoy Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts recommend GNPX or ONCO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genprex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, GNPX or ONCO?

Onconetix has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genprex N/A N/A -$16.23M -$133.36 N/A Onconetix $810K 3.09 -$14.03M $248.12 0.00

Is GNPX or ONCO more profitable?

Genprex has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Genprex's return on equity. Company Net Margins Return on Equity Return on Assets Genprex N/A -163.12% -128.98% Onconetix -1,575.89% -91.95% -53.76%

Do analysts recommend PPBT or ONCO?

Purple Biotech presently has a consensus target price of $30.00, suggesting a potential upside of 1,701.80%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Onconetix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Purple Biotech 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Onconetix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PPBT or ONCO more profitable?

Purple Biotech has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Purple Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Purple Biotech N/A -147.77% -111.59% Onconetix -1,575.89% -91.95% -53.76%

Onconetix (ONCO) Competitors

$0.63 -0.01 (-1.09%)

As of 10:31 AM Eastern

Compare

ONCO vs. PPCB, GOVX, DCOY, GNPX, and PPBT

Should you buy Onconetix stock or one of its competitors? Onconetix's main competitors and comparable companies include Propanc Biopharma (PPCB), GeoVax Labs (GOVX), Decoy Therapeutics (DCOY), Genprex (GNPX), and Purple Biotech (PPBT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Onconetix compare to Propanc Biopharma?

Onconetix (NASDAQ:ONCO) and Propanc Biopharma (NASDAQ:PPCB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Onconetix has higher revenue and earnings than Propanc Biopharma. Propanc Biopharma is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.09	-$14.03M	$248.12	0.00
Propanc Biopharma	N/A	N/A	-$58.92M	-$24.25	N/A

23.9% of Onconetix shares are owned by institutional investors. 0.3% of Onconetix shares are owned by company insiders. Comparatively, 28.5% of Propanc Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Propanc Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Onconetix has a beta of 2.69, indicating that its share price is 169% more volatile than the broader market. Comparatively, Propanc Biopharma has a beta of 3.52, indicating that its share price is 252% more volatile than the broader market.

In the previous week, Propanc Biopharma had 1 more articles in the media than Onconetix. MarketBeat recorded 3 mentions for Propanc Biopharma and 2 mentions for Onconetix. Onconetix's average media sentiment score of 0.93 beat Propanc Biopharma's score of 0.44 indicating that Onconetix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Propanc Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Propanc Biopharma has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Propanc Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Propanc Biopharma	N/A	-151.28%	-109.53%

Summary

Onconetix beats Propanc Biopharma on 8 of the 12 factors compared between the two stocks.

How does Onconetix compare to GeoVax Labs?

Onconetix (NASDAQ:ONCO) and GeoVax Labs (NASDAQ:GOVX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

GeoVax Labs has a consensus target price of $150.00, indicating a potential upside of 22,976.92%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Onconetix has higher revenue and earnings than GeoVax Labs. GeoVax Labs is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.09	-$14.03M	$248.12	0.00
GeoVax Labs	N/A	N/A	-$21.47M	-$11.34	N/A

Onconetix has a beta of 2.69, suggesting that its stock price is 169% more volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.73, suggesting that its stock price is 273% more volatile than the broader market.

In the previous week, GeoVax Labs had 4 more articles in the media than Onconetix. MarketBeat recorded 6 mentions for GeoVax Labs and 2 mentions for Onconetix. Onconetix's average media sentiment score of 0.93 beat GeoVax Labs' score of 0.35 indicating that Onconetix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Onconetix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GeoVax Labs	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

23.9% of Onconetix shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 0.3% of Onconetix shares are owned by insiders. Comparatively, 0.7% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

GeoVax Labs has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
GeoVax Labs	N/A	-743.64%	-394.74%

Summary

Onconetix beats GeoVax Labs on 8 of the 14 factors compared between the two stocks.

How does Onconetix compare to Decoy Therapeutics?

Onconetix (NASDAQ:ONCO) and Decoy Therapeutics (NASDAQ:DCOY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Decoy Therapeutics has a consensus price target of $30.00, indicating a potential upside of 883.93%. Given Decoy Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Decoy Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Decoy Therapeutics has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Decoy Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Onconetix	-1,575.89%	-91.95%	-53.76%
Decoy Therapeutics	N/A	-315.22%	-167.15%

Decoy Therapeutics has lower revenue, but higher earnings than Onconetix. Decoy Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Onconetix	$810K	3.09	-$14.03M	$248.12	0.00
Decoy Therapeutics	N/A	N/A	-$12.52M	-$30.37	N/A

Onconetix has a beta of 2.69, indicating that its stock price is 169% more volatile than the broader market. Comparatively, Decoy Therapeutics has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

23.9% of Onconetix shares are held by institutional investors. Comparatively, 11.9% of Decoy Therapeutics shares are held by institutional investors. 0.3% of Onconetix shares are held by insiders. Comparatively, 1.5% of Decoy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Onconetix and Onconetix both had 2 articles in the media. Decoy Therapeutics' average media sentiment score of 1.43 beat Onconetix's score of 0.93 indicating that Decoy Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Onconetix	Positive
Decoy Therapeutics	Positive

Summary

Onconetix and Decoy Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Onconetix compare to Genprex?

Genprex (NASDAQ:GNPX) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Genprex has a beta of -0.88, meaning that its stock price is 188% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, meaning that its stock price is 169% more volatile than the broader market.

14.1% of Genprex shares are held by institutional investors. Comparatively, 23.9% of Onconetix shares are held by institutional investors. 0.3% of Genprex shares are held by company insiders. Comparatively, 0.3% of Onconetix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genprex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Genprex has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Genprex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genprex	N/A	-163.12%	-128.98%
Onconetix	-1,575.89%	-91.95%	-53.76%

Onconetix has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genprex	N/A	N/A	-$16.23M	-$133.36	N/A
Onconetix	$810K	3.09	-$14.03M	$248.12	0.00

In the previous week, Genprex and Genprex both had 2 articles in the media. Onconetix's average media sentiment score of 0.93 beat Genprex's score of 0.43 indicating that Onconetix is being referred to more favorably in the news media.

Company	Overall Sentiment
Genprex	Neutral
Onconetix	Positive

Summary

Onconetix beats Genprex on 10 of the 11 factors compared between the two stocks.

How does Onconetix compare to Purple Biotech?

Purple Biotech (NASDAQ:PPBT) and Onconetix (NASDAQ:ONCO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings, media sentiment and institutional ownership.

9.6% of Purple Biotech shares are owned by institutional investors. Comparatively, 23.9% of Onconetix shares are owned by institutional investors. 3.0% of Purple Biotech shares are owned by insiders. Comparatively, 0.3% of Onconetix shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Purple Biotech presently has a consensus target price of $30.00, suggesting a potential upside of 1,701.80%. Given Purple Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Purple Biotech is more favorable than Onconetix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Purple Biotech	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Onconetix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Purple Biotech has a net margin of 0.00% compared to Onconetix's net margin of -1,575.89%. Onconetix's return on equity of -91.95% beat Purple Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Purple Biotech	N/A	-147.77%	-111.59%
Onconetix	-1,575.89%	-91.95%	-53.76%

Onconetix has higher revenue and earnings than Purple Biotech. Purple Biotech is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Purple Biotech	N/A	N/A	-$26.39M	-$23.25	N/A
Onconetix	$810K	3.09	-$14.03M	$248.12	0.00

Purple Biotech has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Onconetix has a beta of 2.69, meaning that its share price is 169% more volatile than the broader market.

In the previous week, Purple Biotech and Purple Biotech both had 2 articles in the media. Onconetix's average media sentiment score of 0.93 beat Purple Biotech's score of 0.44 indicating that Onconetix is being referred to more favorably in the news media.

Company	Overall Sentiment
Purple Biotech	Neutral
Onconetix	Positive

Summary

Onconetix beats Purple Biotech on 9 of the 14 factors compared between the two stocks.

Get Onconetix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ONCO vs. The Competition

Export

Metric	Onconetix	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.51M	$4.00B	$7.23B	$12.87B
Dividend Yield	N/A	3.63%	2.54%	11.02%
P/E Ratio	0.00	11.49	272.48	24.29
Price / Sales	3.09	1,304.68	608.54	79.97
Price / Cash	N/A	108.37	79.89	53.65
Price / Book	0.19	16.72	13.12	6.25
Net Income	-$14.03M	-$22.76M	$3.47B	$348.11M
7 Day Performance	-4.95%	3.34%	2.05%	1.47%
1 Month Performance	-22.10%	11.53%	8.25%	4.70%
1 Year Performance	-99.57%	58.10%	26.26%	17.01%

Onconetix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ONCO Onconetix	1.7327 of 5 stars	$0.63 -1.1%	N/A	-99.6%	$2.51M	$810K	0.00	12	Positive News Analyst Upgrade
PPCB Propanc Biopharma	0.5489 of 5 stars	$1.14 -1.7%	N/A	-98.6%	$2.60M	N/A	N/A	1	News Coverage Short Interest Increase Gap Up
GOVX GeoVax Labs	1.6002 of 5 stars	$0.60 -7.3%	$150.00 +24,775.6%	-96.8%	$2.09M	$2.49M	N/A	10	Short Interest Increase Gap Down High Trading Volume
DCOY Decoy Therapeutics	2.7676 of 5 stars	$3.46 -5.7%	$30.00 +767.3%	N/A	$2.04M	N/A	N/A	20	Positive News Short Interest Decrease
GNPX Genprex	0.3065 of 5 stars	$3.98 +0.6%	N/A	-97.9%	$2.00M	N/A	N/A	20	Upcoming Earnings Short Interest Increase Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ONCO) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Onconetix (ONCO) Competitors

ONCO vs. PPCB, GOVX, DCOY, GNPX, and PPBT

How does Onconetix compare to Propanc Biopharma?

Summary

How does Onconetix compare to GeoVax Labs?

Summary

How does Onconetix compare to Decoy Therapeutics?

Summary

How does Onconetix compare to Genprex?

Summary

How does Onconetix compare to Purple Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Onconetix (ONCO) Competitors

ONCO vs. PPCB, GOVX, DCOY, GNPX, and PPBT

How does Onconetix compare to Propanc Biopharma?

Which has better valuation & earnings, ONCO or PPCB?

Do insiders & institutionals hold more shares of ONCO or PPCB?

Do analysts prefer ONCO or PPCB?

Which has more volatility & risk, ONCO or PPCB?

Does the media favor ONCO or PPCB?

Is ONCO or PPCB more profitable?

Summary

How does Onconetix compare to GeoVax Labs?

Do analysts recommend ONCO or GOVX?

Which has stronger valuation & earnings, ONCO or GOVX?

Which has more risk and volatility, ONCO or GOVX?

Does the media prefer ONCO or GOVX?

Do institutionals & insiders have more ownership in ONCO or GOVX?

Is ONCO or GOVX more profitable?

Summary

How does Onconetix compare to Decoy Therapeutics?

Do analysts recommend ONCO or DCOY?

Is ONCO or DCOY more profitable?

Which has stronger earnings and valuation, ONCO or DCOY?

Which has more volatility & risk, ONCO or DCOY?

Do institutionals & insiders believe in ONCO or DCOY?

Does the media prefer ONCO or DCOY?

Summary

How does Onconetix compare to Genprex?

Which has more risk & volatility, GNPX or ONCO?

Do insiders & institutionals believe in GNPX or ONCO?

Do analysts recommend GNPX or ONCO?

Is GNPX or ONCO more profitable?

Which has higher valuation and earnings, GNPX or ONCO?

Does the media favor GNPX or ONCO?

Summary

How does Onconetix compare to Purple Biotech?

Do insiders & institutionals hold more shares of PPBT or ONCO?

Do analysts recommend PPBT or ONCO?

Is PPBT or ONCO more profitable?

Which has stronger earnings & valuation, PPBT or ONCO?

Which has more volatility and risk, PPBT or ONCO?

Does the media favor PPBT or ONCO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ONCO vs. The Competition

Onconetix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools